Search
rabeprazole (Aciphex)
Tradename: Aciphex. Generic approved nov 2013. [2]
Indications:
- duodenal ulcer
- gastroesophageal reflux disease (GERD)
- pyrosis
- prevention of GI bleed due to hypersecretory conditions
- Zollinger-Ellison syndrome
- systemic mastocytosis
- multiple endocrine neoplasia [3]
- reflux esophagitis (treatment & maintenance)
- component of combination therapy for Helicobacter pylori
Dosage: 20 mg PO QD
Tabs: 20 mg (delayed release).
Mechanism of action:
1) proton pump inhibitor
2) interacts with sulfhydryl groups in proton pump
3) inactive at neutral pH
Interactions
drug interactions
drug adverse effects of proton pump inhibitors (PPI)
General
proton pump inhibitor
pyrrole
Properties
INHIBITS: H+/K+ ATPase
Database Correlations
PUBCHEM correlations
References
- Kaiser Permanente Northern California Drug Information, 2000
- FDA News Release: Nov. 8, 2013
FDA approves first generic versions of Aciphex delayed-release
tablets to treat GERD.
http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm374329.htm
- Deprecated Reference